β-casein variants and atherosclerosis—claims are premature

      The possible discovery of a ‘new’ cardiovascular risk factor always arouses interest. Since the factor in question—in this case β-casein A1—is a ubiquitous dietary component and is potentially readily replaceable, possibilities for prevention are exciting. Thus, it is appropriate to examine the evidence at present available to support the claim that β-casein A1 is atherogenic compared with β-casein A2.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Tailford KA, Berry CL, Thomas AC, Campbell JH. A casein variant in cow's milk is atherogenic. Atherosclerosis 2003:170;13–9.

      2. West S, King V, Carey TS, Lohr KN, McKoy N, Sutton SF et al. Systems to rate the strength of scientific evidence. Rockville, MD: Agency for Healthcare Research and Quality; 2002 April 2002. Report No.: Evidence Report/Technology Assessment Number 47.

        • Mann J.
        Discrepancies in nutritional recommendations: the need for evidence based nutrition.
        Asia Pac. J. Clin. Nutr. 2002; 11: S510-S515
        • Clarkson T.B.
        • Lehner N.D.M.
        • Bullock B.C.
        Specialized research applications: I. Atherosclerosis research.
        in: Weisbroth S.H. Flatt R.E. Krauss A.L. The biology of the laboratory rabbit. Academic Press, San Diego1974: 155-165
        • Vivekananthan D.P.
        • Penn M.S.
        • Sapp S.K.
        • Hsu A.
        • Topol E.J.
        Use of antioxidant vitamins for the prevention of cardiovascular disease; meta-analysis of randomised trials.
        Lancet. 2003; 361: 2017-2023